For more than 30 years, Dr. Kenneth LaPensee has provided research and data analysis to support psychiatric and central nervous system (CNS) products. He has analyzed pharmacoeconomic data for medications that target such conditions as autism, Alzheimer's disease, and seizure disorders. Dr. Kenneth LaPensee has also worked with patient data to address quality of life, medication adherence, and other clinical data relevant to pricing, reimbursement, and other economic factors.
Dr. Kenneth LaPensee presently serves as an independent consultant in health economics and outcomes research (HEOR) and market access for Skylands Healthcare Consulting. He comes to this role having served as senior director for economics, reimbursement, and access for The Medicines Company, where he contributed to investigations related to antibiotic development, cardiovascular disease and stroke. While serving in this role, he completed a number of multifaceted studies that he then presented at poster sessions and in peer-reviewed article format.
Previously, as director of health economics at Forest Laboratories,Dr. Kenneth LaPensee chaired a depression working group and represented HEOR interests in steering committees targeted at the funding of research. He came to this role with experience as payer and reimbursement strategies director for the outcomes research unit at Ingenix/i3Innovus, and as an outcomes research contractor for Berlex Laboratories. Dr. LaPensee holds a Ph.D. from the University of Connecticut as well as a Master of Public Health from the University of Medicine and Dentistry of New Jersey, through which he received the honor of an epidemiology internship at the federal level.
